Shilpa Medicare receives approval from USFDA for Irinotecan HCL Injection

01 Jan 2019

Shilpa Medicare has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) Single Dose Vials. Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum.

According to IQVIA MAT Q2 2018 data, the US market for Irinotecan HCL approximately $18 million

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Related Shilpa Medicare Ltd. Links:

Shilpa Medicare Share Price

369.05 1.85 (0.50%) Mar 02, 17:31
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 614.40
Dr. Reddys Lab 4406.20
Lupin 1054.60
Piramal Enterprises 1918.00
Cadila Healthcare 440.95
View more..
Sensex vs Shilpa Medicare
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback